FORT WORTH, TX – June 15, 2022 – Nacuity Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing treatments for retinitis pigmentosa, cataracts and other ocular diseases caused by oxidative stress, today announced the closing of a $16.5 million Series B financing led by Foundation Fighting Blindness and its venture arm RD Fund. Additional existing investors also […]